SEARCH

SEARCH BY CITATION

References

  • 1
    Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2008. NSDUH Series H-34, DHHS Publication No. SMA 08-4343.
  • 2
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Text Revision. Washington, DC: American Psychiatric Association; 2000.
  • 3
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment Episodes Data Set (TEDS) Highlights. Rockville, MD: National Admissions to Substance Abuse Treatment Services; 20052007.
  • 4
    Warner M, Chen LH, Makuc DM. Increase in Fatal Poisonings Involving Opioid Analgesics in the United States, 1999–2006. NCHS Data Brief, No 22. Hyattsville, MD: National Center for Health Statistics; 2009.
  • 5
    White AG, Birnbaum HG, Schiller M, et al. The economic impact of opioid abuse, dependence, and misuse. Am J Pharm Benefits; forthcoming 2011.
  • 6
    Drug Enforcement Administration Website. Office of Diversion Control. Questions and answers: State prescription monitoring programs (updated July 2010). Available at: http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm (accessed October 20, 2010).
  • 7
    Food and Drug Administration, Department of Health and Human Services. FDA identifies first steps in requirements for safety plans for certain drugs and biologics. 2008. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116872.htm (accessed September 8, 2009).
  • 8
    Office of National Drug Control Policy. The Economic Costs of Drug Abuse in the United States: 1992–2002. Washington, DC: Executive Office of the President; 2004.
  • 9
    The National Center on Addiction and Substance Abuse at Columbia University. Shoveling Up II: The Impact of Substance Abuse on Federal, State and Local Budgets. New York, NY. May 2009.
  • 10
    Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Pharm 2009;15(7):55662.
  • 11
    Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001. Clin J Pain 2006;22(8):66776.
  • 12
    White A, Birnbaum H, Mareva M, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11(6):46979.
  • 13
    McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. J Pain Palliat Care Pharmacother 2010;24(1):518.
  • 14
    Bureau of Justice Statistics. Bulletin: Prisoners in 2007. Washington, DC: Office of Justice Programs; 2008.
  • 15
    Bureau of Justice Statistics. Criminal justice expenditure and employment extracts program. Table 1: Percent Distribution of Expenditure for the Justice System, by Type of Government, Fiscal Years 2005–2006. Available at: http://bjs.ojp.usdoj.gov/index.cfm?ty=tp&tid=5 (accessed February 14, 2011).
  • 16
    Federal Bureau of Investigation. Criminal Justice Information Services Division. Crime in the United States, 2007. Available at: http://www2.fbi.gov/ucr/cius2007/index.html (accessed February 14, 2011).
  • 17
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Drug Abuse Warning Network (DAWN), 2007: Area profiles of drug-related mortality. HHS Publication No. SMA 09-4407, DAWN Series D-31. Rockville, MD, 2009.
  • 18
    Centers for Medicare and Medicaid Services. National health expenditure data, personal health care spending by age group and source of payment, calendar year 2004. Available at: http://www.cms.hhs.gov/NationalHealthExpendData/downloads/2004-age-tables.pdf (accessed July 22, 2009).
  • 19
    Hadley J, Holahan J, Coughlin T, Miller D. Covering the uninsured in 2008: Current costs, sources of payment, and incremental costs. Health Aff 2008;27(5):w399415.
  • 20
    Levit KR, Kassed CA, Coffey RM, et al. Projections of National Expenditures for Mental Health Services and Substance Abuse Treatment, 2004–2014. SAMHSA Publication No. SMA 08-4326. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2008.
  • 21
    Mark TL, Levit KR, Coffey RM, et al. National Expenditures for Mental Health Services and Substance Abuse Treatment, 1993–2003 SAMHSA Publication No. SMA 07-4227. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2007.
  • 22
    Miron JA. The budgetary implications of drug prohibition. Criminal Justice Policy Foundation. Dec 2008.
  • 23
    National Center for Health Statistics. Deaths: Final Data for 2006. National Vital Statistics Report Vol 57 No 14. (PHS) 2009-1120.
  • 24
    Office of Diversion Control. National Forensic Laboratory Information System: Year 2007 Annual Report. Washington, DC: U.S. Drug Enforcement Administration; 2008.
  • 25
    Pastore AL, Maguire K. Sourcebook of Criminal Justice Statistics 2003. Table 6.19. Bureau of Justice Statistics. Available at: http://www.albany.edu/sourcebook/tost_6.html (accessed July 22, 2009).
  • 26
    Substance Abuse and Mental Health Services Administration. Office of Applied Studies. Treatment Episodes Data Set (TEDS) 2005: Discharges from Substance Abuse Treatment Services. Rockville, MD.
  • 27
    U.S. Census Bureau. Statistical Abstract of the United States: 2009 (128th Edition), Population: 1960–2007. Washington, DC, 2008. Available at: http://www.census.gov/compendia/statab (accessed July 22, 2009).
  • 28
    U.S. Department of Labor. Bureau of Labor Statistics. Current Population Survey, 2007 Annual Averages—Household Data, Tables 1–3. Washington, DC.
  • 29
    U.S. Department of Labor. Bureau of Labor Statistics. Hourly Compensation Index, Business Sector. Series ID PRS84006103. Washington, DC.
  • 30
    French MT, Popovici I, Tapsell L. The economic costs of substance abuse treatment: Updated estimates and cost bands for program assessment and reimbursement. J Subst Abuse Treat 2008;35:4629.
  • 31
    Goetzel RZ, Long SR, Ozminkowski RJ, et al. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 2004;46(4):398412.
  • 32
    Kaiser Family Foundation. State health facts: Medicaid payments per enrollee, FY2007. Available at: http://www.statehealthfacts.org (accessed October 20, 2010).
  • 33
    Birnbaum H. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics 2005;23(2):1034.
  • 34
    American Society of Interventional Pain Physicians. NASPER: National All Schedules Prescription Electronic Reporting Act. 2007. Available at: http://www.nasper.org (accessed August 31, 2009).
  • 35
    Rappaport BA; Food and Drug Administration, Department of Health and Human Services. NDA approval letter for Embeda; 2009. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022321s000ltr.pdf (accessed August 31, 2009).
  • 36
    Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med 2005;6(2):10712.
  • 37
    White AG, Birnbaum HG, Schiller M, Tang J, Katz NP. Analytic models to identify patients at risk for prescription opioid abuse. Am J Manag Care 2009;15(12):1120.
  • 38
    Ruetsch C. Empirical view of opioid dependence. J Manag Care Pharm 2010;16(Suppl 1b):S913.
  • 39
    Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharmacol 2008;16(5):40516.